234 - Mutations in the epidermal growth factor receptor gene in non-small-cell lung cancer patients and EGFR serum levels

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Thoracic malignancies
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter ELENA Romero-Ventosa
Authors E.Y. Romero-Ventosa1, M. Rodríguez Rodríguez1, S. Gonzalez Costas1, A. GonzÁlez-PiÑeiro2, S. Blanco-Prieto3, M. Páez de La Cadena3, I. Arias Santos1, B. Leboreiro Enriquez1, B. Bernardez Ferran4, E. Brozos5
  • 1Farmacia Hospitalaria, Complejo Hospitalario Universitario de Vigo (CHUVI)-Hospital Xeral-Cíes, 36204 - VIGO/ES
  • 2Pathological Anatomy, Complejo Hospitalario Universitario de Vigo (CHUVI)-Hospital Xeral-Cíes, 36204 - VIGO/ES
  • 3Bioquímica, Genética E Inmunología, Universidad de Vigo, VIGO/ES
  • 4Farmacia Hospitalaria, Complejo Hospitalario Universitario de Santiago (CHUS), SANTIAGO/ES
  • 5Dept. Of Medical Oncology, Complejo Hospitalario Universitario de Santiagode Compostela SERGAS, ES-15706 - Santiago de Compostela/ES



Determine the existing mutations in the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients and correlate with survival. Also pretreatment EGFR serum levels were quantified and analyzed if there were differences between patients with or without mutations.


From July 09 and July 11 serum samples were collected before starting erlotinib. Serum levels of EGFR were quantified using an ELISA. Patients were examined for mutations in tissue by EGFR Mutation Test Kit cobas. SPSS was used to calculate overall survival (OS) and progression-free survival (PFS). Mann-Whitney U test was used for comparison of EGFR serum level.


58 patients were studied but we obtained information of mutations in 34 patients. All variants were found in exons 18, 19 and 21 of EGFR. No mutation was found in exon 20, only two polymorphisms. Of 32 patients analyzed, we detected a total of 11 mutations (34.4%). In exon 19 we found 8 mutations (del19) and affected 8 patients (72.7% mutations). In exon 21 we found two mutations (L858R and L861Q), each in 1 patient (18.2% mutations). In exon 18, G719X mutation was found in 1 patient (9.1% mutations). The remaining patients (65.6%) were wild type. Patients wild type have a median OS of 5.4 months (95% CI, 4.2 - 6.6) and mutated patients 12.6 months (95% CI, 4.7- 21.1); p = 0.033. In terms of PFS, wild type patients have a median PFS of 2.8 months (95% CI: 2.0 - 3.6) and mutated 8.6 months (95% CI 2.0 - 15.1); p = 0.012.

We determined serum levels of EGFR in 44 patients with a mean of 57.5 ng/mL. Of these patients, 21 were wild type, 7 were mutated and 16 showed an unknown mutational status. In wild type patients, the mean serum levels of EGFR was 57.8 ng/mL and in the mutant was 62.3 ng/mL.


Patients with EGFR gene mutation have a higher OS and PFS. No differences were found in EGFR serum levels prior to erlotinib treatment between wild type and mutated patients.


All authors have declared no conflicts of interest.